Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 16 of 16 publications.
Skip to main content
Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Tamhankar MA, Raza S, Brutsaert E, Urdaniz E, Vainilovich Y, Heyes A, Gildea L, Sales-Sanz M. The burden of illness in thyroid eye disease: current state of the evidence. Front Ophthalmol. 2025 Apr 16;5. doi: 10.3389/fopht.2025.1565762
Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184
Yee K, Poulos C, Bussberg C, Myers K. Patient preferences for generalized myasthenia gravis treatment profiles: results of a web-based survey. Poster presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference; March 3, 2024. Orlando, FL.
Gildea L, Copley-Merriman C, Arvin-Berod C, Vande Walle K, Verheesen P, Stoykov I. Evidence gap analysis of the burden of illness and treatment of bullous pemphigoid. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S27. doi: 10.1016/j.jval.2023.09.141
Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Tuson H, Unuigbe A, Bell T. The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price. Value Health. 2023 Mar;26(3):384-91. doi: 10.1016/j.jval.2023.01.004.
Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219
Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022 Jan 24;40(3):483-93. doi: 10.1016/j.vaccine.2021.12.002
Ciarametaro M, Houghton K, Wamble D, Dubois R. The dollar or disease burden: caps on health care spending may save money, but at what “cost” to patients? Value Health. 2021 Mar;24(3):388-96. doi: 10.1016/j.jval.2020.10.024v
Herring W, Rosen B. Economic model for ResVax for maternal vaccination against infant respiratory syncytial virus disease in the United States. Presented at the 2019 Respiratory Syncytial Virus Consortium in Europe; June 2019. Utrecht, The Netherlands.
La EM, Talbird SE, Kanadanian KV, Huang L, Fain J, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019 Apr 3;15(4):978-86. doi: 10.1080/21645515.2018.1556074
Wamble DE, Ciarametaro M, Houghton K, Ajmera M, Dubois RW. What's been the bang for the buck? Cost-effectiveness of health care spending across selected conditions in the US. Health Aff (Millwood). 2019 Jan;38(1):68-75. doi: 10.1377/hlthaff.2018.05158.
La EM, Talbird SE, Kanadanian KV, Fain J, Huang L, Srivastava A. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Poster presented at the 2018 IDWeek Conference; October 4, 2018. San Francisco, CA.
Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301
Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, Stoddard J. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One. 2017 Aug 10;12(8):e0182321. doi: 10.1371/journal.pone.0182321
Herring W, Rosen B. Early economic model for respiratory syncytial virus vaccination in older adults. Presented at the 2017 Respiratory Syncytial Virus Consortium in Europe; May 2017. Antwerp, Belgium.